Effects of aglycone Genistein in a rat experimental model of postmenopausal metabolic syndrome

Journal of Endocrinology

Volumn 200, Issue 3, 2009, Pages 367-376

  Bitto, Alessandra ^a,b   Altavilla, Domenica ^a   Bonaiuto, Antonio ^a   Polito, Francesca ^a   Minutoli, Letteria ^a   Di Stefano, Vincenzo ^a   Giuliani, Daniela ^b   Guarini, Salvatore ^b   Arcoraci, Vincenzo ^a   Squadrito, Francesco ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ARGINASE; GENISTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITROPRUSSIDE SODIUM; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHENYLEPHRINE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTERY DILATATION; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; FEMALE; FOOD INTAKE; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HEART RATE; METABOLIC SYNDROME X; NONHUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; UTERUS WEIGHT; VASOCONSTRICTION; WISTAR KYOTO RAT;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; EATING; FEMALE; GENISTEIN; HYPOGLYCEMIC AGENTS; METABOLIC SYNDROME X; OBESITY; OVARIECTOMY; POSTMENOPAUSE; RATS; RATS, INBRED SHR;

EID: 67449150166     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1677/JOE-08-0206     Document Type: Article

References (42)

1. Alexander J & Clearfield M 2006 Cardiovascular disease after menopause: a growing epidemic. Minerva Ginecologica 58 35-40.
2. Altavilla D, Crisafulli A, Marini H, Esposito M, D'Anna R, Corrado F, Bitto A & Squadrito F 2004 Cardiovascular effects of the phytoestrogen genistein. Current Medicinal Chemistry - Cardiovascular & Hematological Agents 2 179-186.
3. Atteritano M, Marini H, Minutoli L, Polito F, Bitto A, Altavilla D, Mazzaferro S, D'Anna R, Cannata ML, Gaudio A et al. 2007 Effects of the phytoestrogen genistein on some predictors of cardiovascular risk in osteopenic, postmenopausal women: a two-year randomized, doubleblind, placebo-controlled study. Journal of Clinical Endocrinology and Metabolism 92 3068-3075.
4. Bracamonte MP & Miller VM 2001 Vascular effects of estrogens: arterial protection versus venous thrombotic risk. Trends in Endocrinology and Metabolism 12 204-209.
5. Bragt MC & Popeijus HE 2008 Peroxisome proliferator-activated receptors and the metabolic syndrome. Physiology and Behavior 94 187-197.
6. Crisafulli A, Marini H, Bitto A, Altavilla D, Squadrito G, Romeo A, Adamo EB, Marini R, D'Anna R, Corrado F et al. 2004 Effects of genistein on hot flushes in early postmenopausal women: a randomized, double-blind EPT- and placebo-controlled study. Menopause 11 400-404.
7. Crisafulli A, Altavilla D, Marini H, Bitto A, Cucinotta D, Frisina N, Corrado F, D'Anna R, Squadrito G, Adamo EB et al. 2005 Effects of the phytoestrogen genistein on cardiovascular risk factors in postmenopausal women. Menopause 12 186-192.
8. Dang ZC, Audinot V, Papapoulos SE, Boutin JA & Lowik CW 2003 Peroxisome proliferator-activated receptor gamma (PPARgamma) as a molecular target for the soy phytoestrogen genistein. Journal of Biological Chemistry 278 962-967.
9. D'Anna R, Baviera G, Corrado F, Cancellieri F, Crisafulli A & Squadrito F 2005 The effect of the phytoestrogen genistein and hormone replacement therapy on homocysteine and C-reactive protein level in postmenopausal women. Acta Obstetricia et Gynecologica Scandinavica 84 474-477.
10. D'Anna R, Cannata ML, Atteritano M, Cancellieri F, Corrado F, Baviera G, Triolo O, Antico F, Gaudio A, Frisina N et al. 2007 Effects of the phytoestrogen genistein on hot flushes, endometrium, and vaginal epithelium in postmenopausal women: a 1-year randomized, double-blind, placebo-controlled study. Menopause 14 648-655.
11. Davis J, Iqbal MJ, Steinle J, Oitker J, Higginbotham DA, Peterson RG & Banz WJ 2005 Soy protein influences the development of the metabolic syndrome in male obese ZDFxSHHF rats. Hormone and Metabolic Research 37 316-325.
12. Davis J, Higginbotham A, O'Connor T, Moustaid-Moussa N, Tebbe A, Kim YC, Cho KW, Shay N, Adler S, Peterson R et al. 2007 Soy protein and isoflavones influence adiposity and development of metabolic syndrome in the obese male ZDF rat. Annals of Nutrition and Metabolism 51 42-52.
13. Deodato B, Altavilla D, Squadrito G, Campo GM, Arlotta M, Minutoli L, Saitta A, Cucinotta D, Calapai G, Caputi AP et al. 1999 Cardioprotection by the phytoestrogen genistein in experimental myocardial ischaemia-reperfusion injury. British Journal of Pharmacology 128 1683-1690.
14. Dyrskog SE, Jeppesen PB, Colombo M, Abudula R & Hermansen K 2005 Preventive effects of a soy-based diet supplemented with stevioside on the development of the metabolic syndrome and type 2 diabetes in Zucker diabetic fatty rats. Metabolism 54 1181-1188.
15. Ernsberger P, Koletsky RJ, Collins LA & Douglas JG 1993 Renal angiotensin receptor mapping in obese spontaneously hypertensive rats. Hypertension 21 1039-1045.
16. Ernsberger P, Koletsky RJ, Baskin JS & Foley M 1994 Refeeding hypertension in obese spontaneously hypertensive rats. Hypertension 24 699-705.
17. Ernsberger P, Koletsky RJ & Friedman JE 1999a Molecular pathology in the obese spontaneous hypertensive Koletsky rat: a model of syndrome X. Annals of the New York Academy of Sciences 892 272-288.
18. Ernsberger P, Koletsky RJ, Kline DD, Bedol DM & Friedman JE 1999b The SHROB model of syndrome X: effects of excess dietary sucrose. Annals of the New York Academy of Sciences 892 315-318.
19. Freireich EJ, Gehan EA, Rall DP, Schmidt LH & Skipper HE 1966 Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemotherapy Reports 50 219-244.
20. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S et al. 2002 Cardiovascular disease outcomes during 6.8 years of hormone replacement therapy: heart and estrogen/progestin replacement study follow-up (HERS II). Journal of the American Medical Association 288 49-57.
21. Honoré EK, Williams JK, Anthony MS & Clarkson TB 1997 Soy isoflavones enhance coronary vascular reactivity in atherosclerotic female macaques. Fertility and Sterility 67 148-154.
22. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E & for the HERS Research Group 1998 Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Journal of the American Medical Association 280 605-613.
23. Ishizuka T, Ernsberger P, Liu S, Bedol D, Lehman TM, Koletsky RJ & Friedman JE 1998 Phenotypic consequences of a nonsense mutation in the leptin receptor gene (fak) in obese spontaneously hypertensive Koletsky rats (SHROB). Journal of Nutrition 128 2299-22306.
24. Kim S, Shin HJ, Kim SY, Kim JH, Lee YS, Kim DH & Lee MO 2004 Genistein enhances expression of genes involved in fatty acid catabolism through activation of PPARalpha. Molecular and Cellular Endocrinology 220 51-58.
25. Koletsky RJ, Boccia J & Ernsberger P 1995 Acceleration of renal disease in obese SHR by exacerbation of hypertension. Clinical and Experimental Pharmacology and Physiology 22 S254-S256.
26. Li HF,Wang LD & Qu SY 2004 Phytoestrogen genistein decreases contractile response of aortic artery in vitro and arterial blood pressure in vivo. Acta Pharmacologica Sinica 25 313-318.
27. McCarty MF 2006 Isoflavones made simple genistein's agonist activity for the beta-type estrogen receptor mediates their health benefits. Medical Hypotheses 66 1093-1114.
28. Mezei O, Banz WJ, Steger RW, Peluso MR, Winters TA & Shay N 2003 Soy isoflavones exert antidiabetic and hypolipidemic effects through the PPAR pathways in obese Zucker rats and murine RAW 264.7 cells. Journal of Nutrition 133 1238-1243.
29. Paquette A,Wang D, Jankowski M, Gutkowska J & Lavoie JM 2008 Effects of ovariectomy on PPAR alpha, SREBP-1c, and SCD-1 gene expression in the rat liver. Menopause 15 1169-1175.
30. Rosano GM, Vitale C & Tulli A 2006 Managing cardiovascular risk in menopausal women. Climacteric 1 19-27.
31. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC et al. 2002 Writing Group for the Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. Journal of the American Medical Association 288 321-333.
32. Schneider JG, Tompkins C, Blumenthal RS & Mora S 2006 The metabolic syndrome in women. Cardiology in Review 14 286-291.
33. Sinagra D & Conti M 2007 Metabolic syndrome in menopause: physiopathological, clinic and therapeutic aspects for cardiovascular prevention. Recenti Progressi in Medicina 98 185-191.
34. Squadrito F, Altavilla D, Squadrito G, Saitta A, Cucinotta D, Minutoli L, Deodato B, Ferlito M, Campo GM, Bova A et al. 2000 Genistein supplementation and estrogen replacement therapy improve endothelial dysfunction induced by ovariectomy in rats. Cardiovascular Research 45 454-462.
35. Squadrito F, Altavilla D, Morabito N, Crisafulli A, D'Anna R, Corrado F, Ruggeri P, Campo GM, Calapai G, Caputi AP et al. 2002 The effect of the phytoestrogen genistein on plasma nitric oxide concentrations, endothelin-1 levels and endothelium dependent vasodilation in postmenopausal women. Atherosclerosis 163 339-347.
36. Squadrito F, Altavilla D, Crisafulli A, Saitta A, Cucinotta D, Morabito N, D'Anna R, Corrado F, Ruggeri P, Frisina N et al. 2003 Effect of genistein on endothelial function in postmenopausal women: a randomized, doubleblind, controlled study. American Journal of Medicine 114 470-476.
37. Velliquette RA & Ernsberger P 2003 The role of I(1)-imidazoline and alpha(2)-adrenergic receptors in the modulation of glucose metabolism in the spontaneously hypertensive obese rat model of metabolic syndrome X. Journal of Pharmacology and Experimental Therapeutics 306 646-657.
38. Velliquette RA, Koletsky RJ & Ernsberger P 2002 Plasma glucagon and free fatty acid responses to a glucose load in the obese spontaneous hypertensive rat (SHROB) model of metabolic syndrome X. Experimental Biology and Medicine 227 164-170.
39. Vera R, Sánchez M, Galisteo M, Villar IC, Jimenez R, Zarzuelo A, Pérez-Vizcaíno F, Duarte J, Pérez-Vizcaíno F & Duarte J 2007 Chronic administration of genistein improves endothelial dysfunction in spontaneously hypertensive rats: involvement of eNOS, caveolin and calmodulin expression and NADPH oxidase activity. Clinical Science 112 183-191.
40. Vikari J 1976 Precipitation of plasma lipoproteins by PEG-6000 and its evaluation with electrophoresis and ultracentrifugation. Scandinavian Journal of Clinical and Laboratory Investigation 36 265-268.
41. Van Wijk JP, de Koning EJ, Martens EP & Rabelink TJ 2003 Thiazolidinediones and blood lipids in type 2 diabetes. Arteriosclerosis, Thrombosis, and Vascular Biology 23 1744-1749.
42. Yki-Jarvinen H 2004 Thiazolidinediones. New England Journal of Medicine 351 1106-1118.